deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02315430

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum

Sponsor: NRG Oncology

Conditions Fallopian Tube Clear Cell Adenocarcinoma Ovarian Clear Cell Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma
Interventions Cabozantinib S-malate Laboratory Biomarker Analysis
Updated 20 times since 2017 Last updated: Feb 28, 2020 Started: Apr 1, 2015 Primary completion: Feb 9, 2019 Completion: Feb 9, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Fallopian Tube Clear Cell Adenocarcinoma and Ovarian Clear Cell Adenocarcinoma and is currently completed. NRG Oncology leads this study, which shows 20 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Jan 2019 · 5 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Apr 2020 · 11 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 15 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. May 2019 — Apr 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Aug 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Dec 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Jun 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  13. May 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE2

  14. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Abington, United States , Albany, United States , Albuquerque, United States , Ames, United States , Anacortes, United States , Anaheim, United States , Anchorage, United States , Atlanta, United States , Auburn, United States and 261 more locations